The Pharmacovigilance market share in 2026 involves collecting and analyzing safety information to evaluate the risks associated with pharmaceutical products. These activities help manufacturers and healthcare organizations monitor adverse drug reactions, maintain safety records, and meet regulatory reporting requirements. Services and software are used throughout clinical development and after products enter the market. The market is evolving as pharmaceutical companies manage larger volumes of safety data and seek more efficient monitoring processes. Specialized providers support case processing, safety reporting, risk assessment, and regulatory compliance. At the same time, automation and artificial intelligence are creating opportunities to improve data analysis and identify potential safety signals more efficiently.
According to Fortune Business Insights, the global pharmacovigilance market size was valued at USD 9.35 billion in 2025 and is projected to grow from USD 10.54 billion in 2026 to USD 31.56 billion by 2034, exhibiting a CAGR of 14.69% during the forecast period. North America dominated the pharmacovigilance market with a share of 40.84% in 2025. Growing drug development activities, increasing adverse drug reaction reporting, and greater adoption of specialized safety services are supporting market expansion.
Expanding pharmaceutical research and development activities are generating demand for pharmacovigilance services. New medicines and vaccines require systematic safety monitoring during clinical trials and after commercialization. As product pipelines expand, companies need processes that support adverse event collection, evaluation, and reporting across different markets.
Healthcare organizations and pharmaceutical manufacturers are placing greater emphasis on identifying and managing medicine-related risks. Pharmacovigilance helps organizations assess safety information and monitor adverse reactions throughout a product's lifecycle. Greater awareness of adverse drug reaction reporting is supporting investment in dedicated safety teams, service providers, and specialized software.
Artificial intelligence is emerging as an important trend in the pharmacovigilance market. AI-powered tools can help analyze large datasets, identify patterns, and support adverse event detection. In April 2023, Parexel International Corporation entered into a collaboration with Partex to use AI-powered solutions to accelerate drug discovery and development. Such initiatives demonstrate the growing interest in technology-enabled pharmaceutical research and safety processes.
Limited funding and a shortage of trained professionals can constrain pharmacovigilance activities. Effective drug safety monitoring requires specialized knowledge, reliable reporting systems, and resources to meet regulatory requirements. These challenges can be particularly significant in markets where dedicated infrastructure and training opportunities remain limited.